2025 HCPCS code Q5118
(Active) Effective Date: N/A Revision Date: N/A Drugs - Cancer and Vision Associated Drugs Temporary Codes Q0035-Q9992 > Cancer and Vision Associated Drugs Q5112-Q5134 Feed
Biosimilar bevacizumab-bvzr (Zirabev), 10 mg injection for intravenous infusion.
Zirabev is medically necessary for the treatment of specific types of cancers as mentioned in the long description when other treatments are ineffective or inappropriate.
The recommended dosages of biosimilar bevacizumab–bvzr (Zirabev™) vary depending on the condition being treated. Dosages may include 5 mg/kg every 2 weeks, 7.5 mg/kg every 3 weeks, 10 mg/kg every 2 weeks, or 15 mg/kg every 3 weeks in combination with other chemotherapy regimens, depending on the type and stage of cancer.
In simple words: Zirabev is a medicine given through a vein to treat certain types of cancer. This code covers a dose of 10 milligrams.
This code represents 10 mg of biosimilar bevacizumab–bvzr, (Zirabev™) administered by intravenous infusion to treat metastatic colorectal cancer, non–squamous non–small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, and persistent, recurrent, or metastatic cervical cancer.
Example 1: A patient with metastatic colorectal cancer receives 10 mg/kg of Zirabev every 2 weeks as part of their chemotherapy regimen., A patient with recurrent glioblastoma receives 10 mg/kg of Zirabev intravenously every 2 weeks., A patient with persistent, recurrent, or metastatic cervical cancer receives 15 mg/kg of Zirabev intravenously every 3 weeks in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
Documentation should include the diagnosis, the dosage administered, the route of administration, and the medical necessity for the use of Zirabev.
** Report this code for each 10 mg of Zirabev™ administered.
- Specialties:Oncology, Hematology
- Place of Service: Office,Outpatient Hospital, Inpatient Hospital